Press Releases

June 1, 2010

The Observational Medical Outcomes Partnership (OMOP) today announced the winners of its OMOP Cup methods competition, which featured two separate challenges designed to help predict associations between therapeutic drugs and medical outcomes (or adverse events). It encouraged participation from researchers of many fields and entities—both public and private.

May 25, 2010

A new public-private partnership between AstraZeneca and NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will focus on supporting the work of the Drug Induced Liver Injury Network (DILIN). DILIN is a group working to bring together essential scientific and financial resources to better understand drug-induced liver injury as well as effective screening, diagnostic and treatment options.

March 17, 2010

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

March 12, 2010

A new strain of mosquitoes in which females cannot fly may help curb the transmission of dengue fever, according to UC Irvine and British scientists. Dengue fever causes severe flulike symptoms and is among the world’s most pressing public health issues. There are 50 million to 100 million cases per year, and nearly 40 percent of the global population is at risk. The dengue virus is spread through the bite of infected female Aedes aegypti mosquitoes, and there is no vaccine or treatment.

March 1, 2010

The Research Partnership in Cognitive Aging, a public-private effort to promote the study of brain function with age, will award up to $28 million over five years to 17 research grants to examine the neural and behavioral profiles of healthy cognitive aging and explore interventions that may prevent, reduce or reverse cognitive decline in older people.

February 17, 2010

A simple and cheap way of making vaccines stable — even at tropical temperatures — has been developed by scientists at Oxford University and Nova Bio-Pharma Technologies. The British technology has the potential to revolutionise vaccination efforts, particularly in the developing world where infectious diseases kill millions of people every year, by removing the need for fridges, freezers and associated health infrastructure.

January 18, 2010

Together with the Fogarty International Center (FIC), part of the National Institutes of Health, and funded by the Bill & Melinda Gates Foundation, researchers will study the linkages of malnutrition and intestinal infections and how they affect children in the developing world.

January 18, 2010

The use of adiponectin, a hormone derived from fat cells, which is abundant in plasma and easy to measure through commercially available kits, was confirmed as a robust biomarker predictive of glycemic efficacy in Type 2 diabetes and healthy subjects, after treatment with peroxisome proliferator-activated receptor-agonists (PPAR), but not after treatment with non-PPAR drugs such as metformin.

October 29, 2009

The 2009 mHealth (Mobile Health) Summit, organized by the Foundation for the National Institutes of Health (FNIH), today opens an unprecedented two-day summit bringing together more than 800 public and private sector science, medical, policy and mobile technology experts to develop a new roadmap related to the integration of science and wireless solutions to improve public health delivery, particularly to underserved populations, in the U.S. and around theworld.

September 11, 2009

he Boo! Run for Life 10K today announced that it has teamed up with anchor and managing editor of E! News Giuliana Rancic, and television host, speaker, and entrepreneur Bill Rancic in support of renal cell (or kidney) cancer research.